Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals reported strong revenue growth for the half-year ending June 30, 2025, with total revenue reaching $390.4 million, marking a 63% increase from the previous year. Despite the revenue growth, the company recorded an operating loss of $2.3 million due to increased finance costs and investments in research and development. Telix is positioning itself for long-term growth by expanding its product line and geographic reach, notably through the acquisition of RLS Radiopharmacies and the pending approvals of new products.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products. The company is expanding its business operations and investing in research and development to support the launch of new products and enter new markets.
Average Trading Volume: 1,771,469
Technical Sentiment Signal: Sell
Current Market Cap: A$6B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.